Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers.
The synthesis and structure-activity relationships of a series of phenylacetamides related to N-[3-(2,6-dimethyl-1-piperidinyl)propyl]-alpha-phenylbenzeneacetamide (1) (PD85639) acting at the voltage-dependent Na+ channel are described. All structural variations for this study were made in the phenylacetic acid portion of these molecules, and the compounds were synthesized by coupling the appropriately substituted phenylacetic acid derivative with 3-[1-(2,6-dimethyl)piperidinyl]-propanamine using standard methods of amide formation. Compounds were tested as inhibitors of [3H]batrachtoxinin binding in rat neocortical membranes and also as inhibitors of veratridine-induced Na+ influx in Chinese hamster ovary cells expressing type IIA Na+ channels. Diphenylacetic acid derivatives with halogenated aromatic rings (12-15) were very potent in both assays, while alkoxy and alkyl substitution did not affect activity (16 and 17). Selected compounds were tested as potential neuroprotective agents in two cell culture assays involving inhibition of veratridine-induced and hypoxia-induced lactate dehydrogenase release. Compound 15 was equipotent with flunarizine, a reference compound in both neuroprotection assays.
Roufos
I
I
Department of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105.
Hays
S J
SJ
Dooley
D J
DJ
Schwarz
R D
RD
Campbell
G W
GW
Probert
A W
AW
D000081:Acetamides / Q000138:chemical synthesis* / Q000494:pharmacology; D000818:Animals; D001496:Batrachotoxins / Q000378:metabolism; D044482:Benzeneacetamides; D016466:CHO Cells; D015687:Cell Hypoxia; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D006224:Cricetinae; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D010880:Piperidines / Q000737:chemistry* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000378:metabolism; D026941:Sodium Channel Blockers; D013329:Structure-Activity Relationship; D014701:Veratridine / Q000037:antagonists & inhibitors / Q000494:pharmacology
D000081:Acetamides; D001496:Batrachotoxins; D044482:Benzeneacetamides; D010880:Piperidines; D026941:Sodium Channel Blockers; C081801:PD 85639; D014701:Veratridine; D012964:Sodium; D007770:L-Lactate Dehydrogenase